Background: In the recent years, many novel Disease-Modifying Drugs (DMD) have been
introduced to the market in the treatment of multiple sclerosis.
Objectives: To provide the reader with an up to date, compact review on the pharmacokinetic properties,
mechanism of action, and clinical attributes of one of the most recently approved drugs in the
therapy of multiple sclerosis, cladribine.
Conclusion: Cladribine tablets proved to be a highly efficient treatment choice for Relapsing-
Remitting Multiple Sclerosis (RRMS), especially for patients with high disease activity. It is the first
DMD for MS with a complex mechanism of action, by inhibiting the adenosine-deaminase enzyme it
increases the intracellular levels of deoxyadenosine triphosphate, which with relative selectivity depletes
both T- and B-cells lines simultaneously. However long term follow-up safety and effectiveness
data are still missing, and clear treatment protocols are lacking beyond the first two treatment years
cladribine should prove to be a valuable addition to the therapeutic palette of RRMS, and potentially
for Clinically Isolated Syndrome (CIS) as well.